Delonix Bioworks is a clinical-stage biotechnology company at the forefront of developing next-generation genetically engineered bacterial vaccines. Founded by pioneers in synthetic biology and vaccinology, Delonix has developed proprietary genome editing toolkits covering more than 16 bacterial pathogens, targeting priorities on the World Health Organization (WHO) priority pathogens list.

Leveraging these advanced capabilities, we have built three core platforms for innovative vaccine development: OMV Plus™, which produces high-yield, cost-effective outer membrane vesicles designed for superior antigen presentation and immunogenicity; BioDVax, an engineered subunit vaccine platform; and ProBVax, an engineered whole-cell vaccine platform.

Delonix is advancing a robust pipeline of first-in-class and best-in-class programs addressing urgent unmet medical needs, including vaccines for Neisseria meningitidis serogroup B, Bordetella pertussis, Neisseria gonorrhoeae, and Klebsiella pneumoniae.

Delonix Bioworks operates as an independent subsidiary of CuroVax, a vaccine group aimed to becoming an international leader in innovative vaccine development. More information, please visit https://en.curovax.net/